Eisai Says U.S. Approves Oral Form Of Drug For Rare Epilepsy Type
This article was originally published in PharmAsia News
Executive Summary
Eisai said the U.S. FDA has granted approval to market its Banzel (rufinamide) oral drug for treating Lennox-Gastaut syndrome seizures